Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$39.30 +14.7%	$41.14	$30.04 ▼ $67.88	$3.37B	1.85	1.62 million shs	3.65 million shs
NTLA Intellia Therapeutics	$7.41 +9.5%	$9.15	$5.90 ▼ $28.18	$767.06M	2.23	2.32 million shs	2.36 million shs
REGN Regeneron Pharmaceuticals	$554.18 +1.4%	$659.94	$525.99 ▼ $1,211.20	$60.59B	0.44	707,547 shs	1.17 million shs
VRTX Vertex Pharmaceuticals	$484.22 +1.8%	$484.84	$377.85 ▼ $519.88	$124.34B	0.5	1.33 million shs	1.57 million shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	+20.37%	-6.41%	-0.98%	-36.35%
NTLA Intellia Therapeutics	0.00%	+11.76%	-19.63%	-27.35%	-70.30%
REGN Regeneron Pharmaceuticals	0.00%	-3.36%	-18.58%	-20.48%	-40.81%
VRTX Vertex Pharmaceuticals	0.00%	+2.02%	-3.72%	+18.23%	+21.79%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	2.8061 of 5 stars	4.2	1.0	0.0	0.0	2.2	3.3	0.6
NTLA Intellia Therapeutics	4.2992 of 5 stars	4.3	1.0	0.0	4.7	1.7	2.5	1.3
REGN Regeneron Pharmaceuticals	4.7053 of 5 stars	4.4	3.0	1.7	2.3	3.3	1.7	1.9
VRTX Vertex Pharmaceuticals	3.74 of 5 stars	2.3	3.0	0.0	3.3	3.5	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.48	Hold	$73.11	86.02% Upside
NTLA Intellia Therapeutics	2.63	Moderate Buy	$37.56	406.82% Upside
REGN Regeneron Pharmaceuticals	2.76	Moderate Buy	$966.88	74.47% Upside
VRTX Vertex Pharmaceuticals	2.64	Moderate Buy	$512.41	5.82% Upside

Current Analyst Ratings Breakdown

Latest CRSP, VRTX, NTLA, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $84.00
4/1/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$408.00 ➝ $420.00
3/31/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$1,100.00 ➝ $1,000.00
3/31/2025	VRTX Vertex Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$555.00 ➝ $567.00
3/5/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
3/4/2025	NTLA Intellia Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$90.00 ➝ $50.00
2/28/2025	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $26.00
2/28/2025	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $14.00
2/28/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$60.00 ➝ $50.00
2/28/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$91.00 ➝ $68.00
2/28/2025	NTLA Intellia Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell	$9.00

(Data available from 4/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$35M	96.31	N/A	N/A	$22.52 per share	1.75
NTLA Intellia Therapeutics	$57.88M	13.25	N/A	N/A	$11.73 per share	0.63
REGN Regeneron Pharmaceuticals	$14.20B	4.27	$36.39 per share	15.23	$268.50 per share	2.06
VRTX Vertex Pharmaceuticals	$11.02B	11.28	N/A	N/A	$63.90 per share	7.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$4.37	N/A	N/A	N/A	-981.54%	-18.46%	-15.79%	5/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$481.19M	-$5.25	N/A	N/A	N/A	N/A	-49.34%	-40.27%	5/8/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$38.28	14.48	14.58	2.34	31.07%	16.32%	12.76%	4/29/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$2.20	N/A	27.65	2.11	-4.86%	-2.02%	-1.49%	5/5/2025 (Estimated)

Latest CRSP, VRTX, NTLA, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	N/A	N/A	N/A	$11.39 million	N/A
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.24	N/A	N/A	N/A	$2.85 billion	N/A
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	N/A	N/A	N/A	$3.40 billion	N/A
2/11/2025	Q4 2024	CRSP CRISPR Therapeutics	-$1.15	-$0.44	+$0.71	-$0.44	N/A	N/A
2/10/2025	Q4 2024	VRTX Vertex Pharmaceuticals	$3.99	$3.54	-$0.45	$3.50	$2.78 billion	N/A
2/4/2025	Q4 2024	REGN Regeneron Pharmaceuticals	$11.21	$12.07	+$0.86	$8.06	$3.76 billion	$3.79 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$0.88	0.16%	N/A	2.30%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CRSP, VRTX, NTLA, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	22.07	22.07
NTLA Intellia Therapeutics	N/A	6.73	6.73
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
NTLA Intellia Therapeutics	88.77%
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.10%
NTLA Intellia Therapeutics	3.20%
REGN Regeneron Pharmaceuticals	7.48%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	473	85.77 million	82.26 million	Optionable
NTLA Intellia Therapeutics	600	103.52 million	98.59 million	Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.79 million	256.28 million	Optionable

CRSP, VRTX, NTLA, and REGN Headlines

Recent News About These Companies

Zacks Research Has Optimistic Outlook of VRTX Q1 Earnings

April 13 at 8:17 AM | marketbeat.com

Monetary Management Group Inc. Has $244,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 13 at 8:01 AM | marketbeat.com

Kennedy Capital Management LLC Has $9.51 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 13 at 6:45 AM | marketbeat.com

DRW Securities LLC Makes New $479,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 13 at 6:08 AM | marketbeat.com

Advisory Services Network LLC Lowers Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 13 at 5:55 AM | marketbeat.com

FIL Ltd Has $37.56 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 13 at 5:35 AM | marketbeat.com

Zacks Research Has Positive Estimate for VRTX Q1 Earnings

April 13 at 2:01 AM | americanbankingnews.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by Brokerages

April 13 at 1:21 AM | marketbeat.com

Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF Research

April 12 at 12:03 PM | gurufocus.com

Andrew Hill Investment Advisors Inc. Sells 2,335 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 12 at 9:24 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Treasurer of the State of North Carolina

April 12 at 8:47 AM | marketbeat.com

F M Investments LLC Has $12.45 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 12 at 7:15 AM | marketbeat.com

Bank of Nova Scotia Reduces Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 12 at 6:21 AM | marketbeat.com

APG Asset Management US Inc. Sells 666 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 11 at 7:28 AM | marketbeat.com

Vertex Pharmaceuticals Inc (VRTX) Celebrates Prestigious Award for Cystic Fibrosis Research | ...

April 11 at 7:08 AM | gurufocus.com

Martingale Asset Management L P Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 11 at 6:55 AM | marketbeat.com

Azimuth Capital Investment Management LLC Has $8.92 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 11 at 6:54 AM | marketbeat.com

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

April 11 at 5:30 AM | businesswire.com

Arrowstreet Capital Limited Partnership Takes $3.73 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 11 at 4:03 AM | marketbeat.com

Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise

April 10 at 9:39 AM | insidermonkey.com

APG Asset Management N.V. Raises Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 10 at 8:32 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP, VRTX, NTLA, and REGN Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$39.30 +5.04 (+14.71%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$39.11 -0.19 (-0.49%)

As of 04/11/2025 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Intellia Therapeutics NASDAQ:NTLA

$7.41 +0.64 (+9.45%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$7.30 -0.11 (-1.48%)

As of 04/11/2025 07:43 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$554.18 +7.79 (+1.43%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$554.16 -0.01 (0.00%)

As of 04/11/2025 07:54 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$484.22 +8.73 (+1.84%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$487.11 +2.89 (+0.60%)

As of 04/11/2025 06:52 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time